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Sonographically Guided Core Biopsy of
the Breast: Comparison of 14-Gauge
Automated Gun and 11-Gauge Directional
Vacuum-Assisted Biopsy Methods
Objective: To compare the outcomes of 14-gauge automated biopsy and 11-
gauge vacuum-assisted biopsy for the sonographically guided core biopsies of
breast lesions.
Materials and Methods: We retrospectively reviewed all sonographically guid-
ed core biopsies performed from January 2002 to February 2004. The sono-
graphically guided core biopsies were performed with using a 14-gauge automat-
ed gun on 562 breast lesions or with using an 11-gauge vacuum-assisted device
on 417 lesions. The histologic findings were compared with the surgical, imaging
and follow-up findings. The histologic underestimation rate, the repeat biopsy rate
and the false negative rates were compared between the two groups.
Results: A repeat biopsy was performed on 49 benign lesions because of the
core biopsy results of the high-risk lesions (n = 24), the imaging-histologic discor-
dance (n = 5), and the imaging findings showing disease progression (n = 20).
The total underestimation rates, according to the biopsy device, were 55%
(12/22) for the 14-gauge automated gun biopsies and 36% (8/22) for the 11-
gauge vacuum-assisted device (p = 0.226). The atypical ductal hyperplasia
(ADH) underestimation (i.e., atypical ductal hyperplasia at core biopsy and carci-
noma at surgery) was 58% (7/12) for the 14-gauge automated gun biopsies and
20% (1/5) for the 11-gauge vacuum-assisted biopsies. The ductal carcinoma in
situ (DCIS) underestimation rate (i.e., ductal carcinoma in situ upon core biopsy
and invasive carcinoma found at surgery) was 50% (5/10) for the 14-gauge auto-
mated gun biopsies and 41% (7/17) for the 11-gauge vacuum-assisted biopsies.
The repeat biopsy rates were 6% (33/562) for the 14-gauge automated gun biop-
sies and 3.5% (16/417) for the 11-gauge vacuum-assisted biopsies. Only 5 (0.5%)
of the 979 core biopsies were believed to have missed the malignant lesions. The
false-negative rate was 3% (4 of 128 cancers) for the 14-gauge automated gun
biopsies and 1% (1 of 69 cancers) for the 11-gauge vacuum-assisted biopsies.
Conclusion: The outcomes of the sonographically guided core biopsies per-
formed with the 11-gauge vacuum-assisted device were better than those out-
comes of the biopsies performed with the 14-gauge automated gun in terms of
underestimation, rebiopsy and the false negative rate, although these differences
were not statistically significant.
mage-guided core biopsy is considered as an accepted alternative to
surgical biopsy for the histologic assessment of breast lesions. It is a fast,
safe, accurate, economic technique, and it is effective for minimizing the
patients’ discomfort (1 5). Guidance for percutaneous biopsy is usually provided by
stereotaxis or by sonography. The advantages of sonography as a guidance modality
for percutaneous breast biopsy include the lack of ionization radiation, the use of
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ization (1 3). For those lesions amenable to either
stereotatic or sonography guided biopsy, sonography
guided biopsy is preferable in terms of patient comfort,
procedure time and cost (2, 3, 5).
The shortcomings of percutaneous image-guided core
biopsy, namely, the histologic underestimation and the
false negative diagnoses, continue to persist despite the use
of large core needles and the improvements of the biopsy
device. The previously published data has reported a 20%
to 56% atypical ductal hyperplasia (ADH) underestima-
tion, a 16% to 35% ductal carcinoma in situ (DCIS)
underestimation, and a 3% to 11% false-negative rate for
the 14-gauge automated core biopsy method (6 8). In the
case of stereotactically guided core biopsy, many studies
have demonstrated the advantages of 11-gauge vacuum-
assisted biopsy over the 14-gauge automated biopsy with
respect to lower underestimation (9 12), the need for
rebiopsies (13), and the higher calcification retrieval rates
(14, 15), because of its ability to extract more tissue (16).
The benefit of vacuum-assisted biopsy has also been
emphasized by some investigators for sonographically
guided core biopsy (17). However, the advantages of the
11-gauge vacuum-assisted biopsy over the 14-gauge
automated biopsy have not been established for the
sonographically guided core biopsy (18).
This study was undertaken to compare the outcomes of
sonographically guided core biopsies that were performed
with a 14-gauge automated gun with those performed by
using an 11-gauge vacuum-assisted device. The primary
objective was to compare the histologic underestimation
rates, the rebiopsy rates and the false negative rates of
these two sonographically guided core biopsy methods.
MATERIALS AND METHODS
Patients and Biopsy Procedures
From January 2002 to February 2004, sonographically
guided breast biopsies were performed on 979 consecutive
lesions in 940 patients (age range, 13 88 years; mean age,
46.7 years) at our institution. Of these biopsies, 562
biopsies in 525 patients were performed with using a 14-
gauge automated gun (Pro-Mag 2.2, Manan Medical
Products, Northbrook, IL). Of these 525 patients, 490
patients had a biopsy for one lesion, 33 patients had
biopsies for two separate lesions and two patients had
biopsies for three separate lesions. Four hundred and
seventeen biopsies in 415 patients were performed with
using an 11-gauge vacuum-assisted device (Mammotome;
Ethicon-Endosurgery, Cincinnati, OH). Of these 415
patients, 413 patients had a biopsy of one lesion and two
patients had biopsies for two separate lesions. For all the
979 lesions, the referring physicians reported that 180 of
them (18%) were palpable. An informed consent was
obtained from every patient.
The breast biopsy device that was used depended
primarily on the preference of the radiologist performing
the biopsy, although the physician’s and patient’s prefer-
ences also affected this decision. The vacuum-assisted
device was preferred for those lesions for which the
potential benefits of the device were suggested (14, 17,
19); these lesions included calcified lesions, intraductal
lesions and solid nodules of < 1.0 cm. The automated gun
biopsy was preferred for the multifocal lesions and for the
lesions in the subareolar or axillary area. There were no
significant differences between the two study groups for
the patients’ ages, the lesion characteristics or histologic
diagnoses (Tables 1, 2). The percentage of microcalcifica-
tion lesions, as compared with that of the mass lesions, was
significantly higher for the vacuum-assisted method than
for the automated method (p < 0.001) (Table 1).
All biopsies were guided by using high-resolution
sonography units with 10- or 12 MHz linear transducers
(Kretz-Medison, Seoul; HDI 5000, Advanced Technology
Laboratories, Bothell, WA) with the patient placed in the
supine or oblique supine position. The mean number of
core samples obtained with the 14-gauge automated gun
was 4.5 (range, 3 10), and the mean number of core
sample biopsies performed with the 11-gauge vacuum-
14-Gauge Automated Gun versus 11-Gauge Directional Vacuum-Assisted Core Biopsy in Breast Lesions
Korean J Radiol 6(2), June 2005 103
Table 1. The Patient and Lesion Variables for 14-gauge
Automated Biopsies and 11-gauge Vacuum-
assisted Biopsies
Variables Gun (n = 562)VA   (n = 417) p
Patient age (y) 0.554
Mean plus or minus SD    46.7 10.8 46.5 9.7
Age range 14 88 13 79
Lesion type < 0.001
No. of masses 551 (98.0) 384 (92.1)
No. of calcifications 11 (2.0) 33 (7.9)
Maximum lesion size (mm) < 0.001
Mean plus or minus SD 15.5 1.1 13.0 0.8
Range 4 100 3 55
BI-RADS Category 0.061
2 04 (0.7) 05 (1.2)
3 123 (21.9) 097 (23.3)
4a 297 (52.8) 226 (54.2)
4b 087 (15.5) 071 (17.0)
5 51 (9.1) 18 (4.3)
Note. The numbers in the parentheses are percentages.
Gun = 14-gauge automated gun biopsy,    VA = 11-gauge vacuum-
assisted biopsy,    SD = standard deviation,  BI-RADS = Breast Imaging
Reporting and Data Systemassisted device was 10.2 (range, 6 30) (11, 17, 18). When
a lesion that contained microcalcifications was biopsied,
the specimen radiographs were obtained to document the
presence of calcifications. Among the 44 lesions with
calcifications, 75% of the calcifications were identified on
the specimen radiographs. About 20% of the biopsies were
performed by one of two attending radiologists who had 2-
3 years experience with breast sonography and interven-
tion. The other 80% of the biopsies were performed by
four fellows after the first five to 10 biopsies were done
under the supervision of one of the two attending breast
imaging radiologists.
Imaging Evaluation
The characteristics of the lesions during mammography
or sonography were described by consensus between the
two radiologists prior to the biopsy in terms of the lesion
type and size, and with using the guidelines of the
American College of Radiology Breast Imaging Reporting
and Data System (BI-RADS) final assessment categories
(20, 21). All the lesions were classified as either calcifica-
tions or masses. If the calcifications were without an associ-
ated mass, architectural distortion or asymmetric density
on the mammography, then they were classified as
calcifications. Any mass or architectural distortion or
asymmetric density seen on mammography, with or
without calcifications, was classified as a mass. The
maximum diameter of a lesion was measured by sonogra-
phy. All the lesions were categorized according to the BI-
RADS final assessment protocol as modified by Dr.
Stavros. Category 4 was subclassified into 4a and 4b using
the criterion of a 50% probability of malignancy (21).
Thus, category 4a included the lesions with a risk from >
2% to < 50%, and category 4b included the lesions with a
risk from > 50% to < 90%. Category 4 and 5 lesions were
considered as indications for biopsy, and the category 3
lesions (probably benign) or category 2 lesions (benign),
for which biopsies were requested by the physician or
patient, were also biopsied.
Histology Evaluation and Imaging Follow-up
The pathologic lesions were classified as malignant
(invasive ductal carcinoma, DCIS, invasive lobular
carcinoma and other malignancies including lymphoma
and malignant phyllodes tumor), high-risk (ADH, atypical
papillary tumor, radial scar, benign phyllodes tumor,
lobular carcinoma in situ and mucocele-like tumor), or
benign (fibroadenoma, papilloma and nonspecific benign
disease including fibrocystic change, benign mammopathy,
adenosis and ductal epithelial hyperplasia, and specific
benign disease including ductectasia, tubular adenoma,
abscess and fat necrosis).
The patients with a biopsy result of malignancy and
high-risk lesions received surgical excision. If a lesion had a
highly suspicious sonographic finding, then surgical
excision was recommended, despite a benign pathologic
result. If a lesion’s imaging was determined to be concor-
dant with benign pathology, then six, 12 and 24 months
follow-up was recommended.
Mammographic and sonographic follow-ups were
performed for 450 (60%) of the 750 benign lesions, for
247 (61%) of the 406 benign lesions that received 
14-gauge automated gun biopsy and for 203 (59%) of the
344 benign lesions that received 11-gauge vacuum-assisted
biopsy. The mean duration of the follow-up was 9.2
months (range, 1 28 months) for the 14-gauge automated
gun biopsy, and it was 8.8 months (range, 1 25 months)
for the 11-gauge vacuum-assisted biopsy.
Outcome Analysis
Histologic underestimation was considered when the
ADH at the core biopsy was upgraded to carcinoma at
surgery (ADH underestimation), or when the DCIS at the
core biopsy was upgraded to invasive carcinoma at surgery
(DCIS underestimation). The underestimation rate of ADH
or DCIS was determined by dividing the total number of
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Table 2. Histologic Diagnosis of the Core Biopsy Specimens
Gun (n = 562) VA   (n = 417)
Malignant
Invasive ductal carcinoma 100 44
Ductal carcinoma in situ 10 20
Invasive lobular carcinoma 2 0
Others 2   01
114 (20.3) 65 (15.6)
High-risk
Atypical ductal hyperplasia 14 10
Lobular carcinoma in situ 1 1
Radial scar 1 2
Phyllodes tumor 3 2




Other benign 54 20
Benign nonspecific 232 184
428 (76.2) 336 (80.6)
Insufficient sample 1 (0.2) 1 (0.2)
Note. The numbers in parentheses are percentages.  Gun = 14-gauge
automated gun biopsy,    VA = 11-gauge vacuum-assisted biopsy,
malignant lymphoma, granular cell tumor,  malignant spindle cell tumorlesions, for which excisional biopsy was performed, into
the number of lesions that proved to be DCIS or invasive
carcinoma upon excision.
When a repeat biopsy was performed, the time interval
and the reason for the second biopsy were recorded. An
immediate re-biopsy was considered when the repeat
biopsy was performed before the first sonographic follow-
up. A delayed rebiopsy was considered when the repeat
biopsy was performed after a sonographic follow-up. The
reasons for a second biopsy were a high-risk lesion, insuffi-
cient sampling, imaging-histologic discordance and disease
progression, as noted by the imaging findings. Surgical
excision was performed for 19 benign lesions due to the
patient’s request and these were excluded from the final
analysis. The rebiopsy rate was determined by dividing the
total number of core biopsies into the number of repeat
biopsies.
A false-negative diagnosis was defined as a lesion that
showed a benign pathology upon core biopsy, but it was
malignant upon the subsequent surgical biopsy or repeat
core biopsy. The false-negative rate was determined by
dividing the total number of carcinomas found upon
subsequent biopsy into the number of those lesions that
were previously considered benign upon core biopsy (6).
For those patients having a benign biopsy result without
any follow-up imaging, cross-referencing with the national
cancer registries was performed to find out if there was
any additional false negative diagnosis.
Statistical Analysis
Statistical comparison was performed between the 14-
gauge automated biopsy group and the 11-gauge vacuum-
assisted biopsy group in terms of the underestimation,
rebiopsy and the false-negative rates. We also analyzed
whether there was any difference between these results
according to the characteristics of the lesions, i.e., lesion
type (mass or calcifications), lesion sizes and BI-RADS
categories. We used 2 cm as the size criterion. Statistical
analysis was performed using the chi-square test or Fisher’s
exact test. For all the analyses, the results were considered
statistically significant if the p values were < 0.05.
RESULTS
Histologic Underestimation
Surgery was performed for 12 of the 14 ADH lesions
and for 10 of the 10 DCIS lesions in the group that was
biopsied with the 14-gauge automated gun, and surgery
was performed for 5 of the 10 ADH lesions and for 17 of
the 20 DCIS lesions in the group that was biopsied with
the 11-gauge vacuum-assisted device.
The total underestimations, according to biopsy device,
were 56% (12/22) for the 14-gauge automated gun
biopsies and 36% (8/22) for the 11-gauge vacuum-assisted
device. The ADH underestimation rate was 58% (7/12) for
the 14-gauge automated gun biopsies, and it was 20%
(1/5) for the 11-gauge vacuum-assisted biopsy device. The
DCIS underestimation rate was 50% (5/10) for the 14-
gauge automated gun biopsies versus 41% (7/17) for the
11-gauge vacuum-assisted biopsy. However, these differ-
ences were not statistically significant (p = 0.226).
According to the lesion type, the histologic underestima-
tion rate was 60% (6/10) for the calcifications and 41%
(14/34) for the masses (p = 0.293). According to the lesion
size, the histologic underestimation rate was 34% (9/12)
for the lesions of 21 mm or more, and the histologic
underestimation rate was 70% (11/32) for lesions less than
20 mm (p = 0.04). According to the BI-RADS categories,
88% (7/8) of the BI-RADS category 5 lesions were
underestimated whereas 33% (1/3) of the category 3
lesions were underestimated, 50% (6/12) of the category
4a lesions were underestimated and 27% (6/21) of the
category 4b were underestimated (p = 0.04). When the
underestimation rates were compared for the two groups
(Table 3), only the difference for the BI-RADS category 4b
lesions was statistically significant (56% [5/9] and 8%
[1/12]) (p = 0.046).
Repeat Biopsy
Diagnostic repeat biopsies were performed in 49 (5%) of
the 979 lesions: surgical biopsy was done for 48 lesions
and vacuum-assisted biopsy was done for one gun-biopsied
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Table 3. Underestimation Rates for the Two Biopsy Methods
According to Lesion Characteristics
Variables Gun VA    Total p
Total 12/22 (54.5) 8/22 (36.4) 20/44 (45.5) 0.226
Lesion type
Mass 11/20 (55.0) 3/14 (21.4) 14/34 (41.2) 0.079
Calcification 001/2 (50.0) 05/8 (62.5) 06/10 (60.0) 1.000
Lesion size (mm)
1 to 10 004/8 (50.0) 03/9 (33.3) 7/17 (41.2) 0.637
11 to 20 003/9 (33.3) 01/6 (16.7) 4/15 (26.7) 0.604
21 or more .05/5 (100) 04/7 (57.1) 9/12 (75.0) 0.205
BI-RADS category
3 001/3 (33.3) 0 01/3 (33.3)
4a 004/8 (50.0) 02/4 (50.0) 6/12 (50.0) 1.000
4b 005/9 (55.6) 1/12 (8.3)0 6/21 (28.6) 0.046
5 002/2 (100) 05/6 (83.3) 07/8 (87.5) 1.000
Note. The numbers in parentheses are percentages.
Gun = 14-gauge automated gun biopsy,    VA = 11-gauge vacuum-
assisted biopsy,  BI-RADS = Breast Imaging Reporting and Data Systemlesion. The repeat biopsy rate was 6% (33/562) for the 14
gauge-automated gun biopsies, and 4% (16/417) for the
11-gauge vacuum-assisted biopsies. This difference was not
statistically significant (p = 0.19) (Table 4).
Immediate rebiopsy was performed for 4% (21/562) of
the 14-gauge automated gun biopsies and for 2% (8/417)
of the 11-gauge vacuum-assisted biopsies. Five of 21
immediate rebiopsies were due to imaging-histologic
discordance for the 14-gauge automated gun biopsies,
whereas none of the immediate rebiopsies were due to
imaging-histologic  discordance for the 11-gauge vacuum-
assisted biopsies. Delayed repeat biopsy was performed for
2% (12/562) of the 14-gauge automated gun biopsies and
for 2% (8/417) of the 11-gauge vacuum-assisted biopsies
due to the imaging findings of disease progression. This
difference was not statistically significant (p = 0.19).
False Negative Diagnosis
Of the 49 repeated biopsies, 18 (37%) of these lesions
were diagnosed as malignant: 13 lesions (40%, 13/33
rebiopsies) that were sampled with 14-gauge automated
gun biopsy and five lesions (31%, 5/16 rebiopsies) that
were sampled with 11-gauge vacuum-assisted biopsy were
diagnosed as malignant (Table 4). This difference was not
statistically significant (p = 0.579). Eight ADH lesions were
noted upon core biopsy (seven lesions by 14-gauge
automated gun and one lesion by 11-gauge vacuum-
assisted biopsy) and five phyllodes tumors were found to
be malignant upon surgical excision; all these were consid-
ered to be histologic underestimates and not false-negative
findings. Excluding the ADH underestimations and
phyllodes tumors, four benign lesions by 14-gauge
automated gun biopsy and one benign lesion by 11-gauge
vacuum-assisted biopsy were found to be malignant upon
surgical excision. Thus, four (3%) of the 128 lesions with a
final diagnosis of carcinoma via 14-gauge automated gun
biopsy, and one (1%) of the 69 lesions with a final diagno-
sis of carcinoma via 11-gauge vacuum-assisted biopsy
constituted the false-negative diagnoses. No statistically
significant difference was found between the two methods
in terms of a false negative diagnosis (p = 0.659).
The five false-negative cases are summarized at Table 5.
Immediate repeat biopsy with the 14-gauge automated gun
was performed on a 0.8 cm sized category C4b mass with
a nonspecific benign histology due to the imaging-
histologic discordance, and invasive ductal carcinoma was
finally found at surgery. Delayed repeat biopsies due to
the progression of suspicious imaging findings revealed two
DCIS lesions and one invasive ductal carcinoma in the 14-
gauge automated gun biopsy group, and one DCIS in the
11-gauge vacuum-assisted biopsy group (Table 5). There
were no additional false negative cases found by checking
and cross-referencing with the national cancer registries.
DISCUSSION
The results of our study showed that the outcomes of the
sonographically guided core biopsies performed with the
11-gauge vacuum-assisted device were better than those
biopsies performed with the 14-gauge automated gun in
terms of underestimation, rebiopsy and the false negative
rates. The underestimation rate was 55% (12/22) for the
14-gauge automated gun biopsies and 36% (8/22) for the
11-gauge vacuum-assisted device. The repeat biopsy rate
was 6% (33/562) for the 14-gauge automated gun biopsies
and 4% (16/417) for the 11-gauge vacuum-assisted
biopsies. The false-negative rate was 3% (4/128) for the
14-gauge automated gun biopsies and 1% (1/69) for the
11-gauge vacuum-assisted biopsies; however, this differ-
ence for the false-negative rate was not statistically signifi-
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Table 4. Reasons for Diagnostic Rebiopsy after Core Biopsy
Gun VA   
Immediate rebiopsy
High-risk lesion 16 08
Imaging-histologic discordance 05 00
Delayed rebiopsy
Progression of imaging 12 08
Total 33 16
Note. Gun: 14-gauge automated gun biopsy,    VA: 11-gauge vacuum-
assisted biopsy
Table 5. The Patient and Lesion Variables for the Five False-Negative Lesions
Biopsy Age (years) Type Size (mm) Category Histology at Biopsy Interval   (months) Histology at Surgery
14G 47 M 08 4b Benign mammopathy 02 Invasive ductal carcinoma
14G 32 M 13 4a Fibrocystic change 06 Ductal carcinoma in situ
14G 63 M 05 4b Benign mammopathy 09 Invasive ductal carcinoma
14G 62 C 13 4a Benign mammopathy 23 Ductal carcinoma in situ
11G 45 C 15 4b Fibrocystic change 07 Ductal carcinoma in situ
Note. category according to Breast Imaging Reporting and Data System,    the time interval between the initial core biopsy and the repeat biopsy
G = gauge, M = mass, C = calcificationscant.
Histologic underestimation occurs when the percuta-
neous biopsy identifies the presence of a high risk or
malignant lesion, but the pathology is incompletely charac-
terized. Because most ADH and DCIS lesions contain
calcifications, the histologic underestimates upon percuta-
neous biopsy are most often encountered for the calcific
lesions (14, 15). In our study, the underestimation rate was
1.5 times more frequent for the 14-gauge automated gun
biopsies than for the 11-gauge vacuum-assisted device,
although the percentage of the calcified lesions versus mass
lesions was significantly higher for the vacuum-assisted
method (8%) than for the automated method (2%).
According to the BI-RADS categories, 88% (7/8) of the BI-
RADS category 5 lesions were underestimated, whereas
33% (1/3) of the category 3 lesions and 36% (12/33) of
the category 4 lesions were underestimated (p = 0.04).
When the underestimation rates were compared between
the two groups (Table 3), the difference for the BI-RADS
category 4b lesions was found to be significant (56% [5/9]
and 8% [1/12]) (p = 0.046). The histologic underestimates
for percutaneous biopsy seem to be related to the lesion’s
BI-RADS categories as well as to the type of lesion (5) and
further investigation on this relationship is needed.
Philpotts et al. (18) have recently compared the
outcomes of sonographically guided core biopsies that
were performed with a 14-gauge automated gun with
those that were performed with an 11-gauge vacuum-
assisted device. Immediate rebiopsy was recommended for
14% (25/181) of the 14-gauge samplings and for 17%
(17/100) of the 11-gauge vacuum-assisted sonographically
guided core biopsies. These rates are much higher than our
rebiopsy rates of 6% (33/562) and 4% (16/417), respec-
tively. Their reasons for rebiopsy and the number of cores
from the 11-gauge vacuum-assisted biopsy were notably
different from those in our study. In their study, 65%
(11/17) of the rebiopsies for the 11-gauge vacuum-assisted
sonographically guided core biopsies were due to imaging-
pathologic discrepancies, whereas none of the rebiopsies
were due to imaging-pathologic discrepancies in our series.
For the biopsies performed using the 11-gauge vacuum-
assisted device, the mean number of core samples in
Philpotts’ study was 5.8 (range, 1 12), but the mean
number of core samples in our study was 10.2 (range, 6
30). At our institution, the acquisition of greater amounts
of tissue was encouraged by the more subtle sonographic
findings such as calcified lesions, intraductal lesions and
solid nodules less than 1.0 cm. Although complete lesion
removal is generally not the goal of percutaneous biopsy,
there is a much reduced chance of sampling error and of a
consequent false-negative diagnosis with the complete or
near complete removal of the sonographic evidence, i.e.,
the lesion (16, 17, 22).
The most obvious shortcoming of core biopsies of the
breast is the possibility of a false-negative diagnosis.
Percutaneous large-core breast biopsy carries with it an
overall false-negative rate of 3% to 11% (23 26). Most of
the false-negatives were due to the biopsy of calcifications,
where the mass false-negative rate was 1%. The reported
missed cancer rate for sonographically guided core biopsy
is very low (1 5, 25): it was only 0.5% (3/687) for the 14-
guage automated gun biopsies in Berg’s study (26), and
0.5% (1/181) for the 14-guage automated gun biopsies and
1% (1/100) for the 11-gauge vacuum-assisted biopsies in
Philpotts’ study (18). Our results are comparable with
those results of previous studies when using a similar
biopsy technique and fellows as operators (18, 26). In our
series, five (0.5%) of the 979 core biopsies were believed
to have missed the lesion: one (0.2%) of the 417 vacuum-
assisted biopsies and four (0.7%) of the 562 automated
gun biopsies. All the carcinomas that were missed in our
study were less than 1.5 cm, as observed upon sonogra-
phy, and this finding was concordant with other studies
(26). For very small lesions, sonographic images can make
it appear as if the needle is within a lesion when the needle
is, in fact, only adjacent to the lesion (4). Another notable
finding in this study was that two (40%) of the five missed
cancers were calcifications, whereas only 5% (44/979) of
the total lesions were calcifications. For the two missed
cancers, calcification retrieval was not confirmed by
performing radiography. Therefore, to reduce the number
of false negative diagnoses, an immediate repeat biopsy
should be recommended if there is any imaging-histologic
discordance or if the calcifications are not retrieved (15).
Our study has the following limitations. Imaging follow-
ups by mammography and sonography were performed
for only about 60% of the lesions that were benign upon
core biopsy. The mean duration of follow-up was 9.0
months (1 28 months), and this was insufficient to
accurately estimate the false negative rate, although we
checked for these patients with using the national cancer
registries. Another limitation was the inclusion of calcified
lesions as a target for sonographically guided core biopsies,
and also there was the preponderance of calcified lesions
that were biopsied by 11-gauge vacuum-assisted biopsy
over the 14-gauge automated gun biopsy. In our institu-
tion, if lesions are evident upon sonography, then the
calcifications are also subjected to sonographically guided
core biopsy because the sampling of the sonographically
visible component often helps target the invasive
component (27, 28). The calcified lesions are the main
cause for histologic underestimation, missed cancer and
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histologic heterogeneities. Further investigation on
sonographically guided core biopsy of calcifications, includ-
ing the randomization of the lesion type and size, is
needed for making an accurate comparison.
In conclusion, sonographically guided core biopsy is an
accurate method for evaluating those breast lesions that
require the physician to perform tissue sampling. In our
series, we believe that only five (0.5%) of the 979 core
biopsies missed the target lesions. The outcomes of
sonographically guided core biopsies performed with the
11-gauge vacuum-assisted device were better than those
biopsies performed with the 14-gauge automated gun in
terms of underestimation, rebiopsy and the false negative
rate, although these differences were not statistically signif-
icant. Yet, this does not mean that we recommend
vacuum-assisted biopsy rather than automated gun biopsy
for all the sonographic masses seen in clinical practice.
When deciding which biopsy method is the most effective,
another factors such as cost, the time required for the
biopsy and the complications, which were all beyond the
scope of this study, should be taken into considered.
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